T cell activation regulates CD6 alternative splicing by transcription dynamics and SRSF1

Journal of Immunology

Volumn 193, Issue 1, 2014, Pages 391-399

  Da Glória, Vânia G ^a   De Araújo, Mafalda Martins ^a,b,c   Santos, Ana Mafalda ^a   Leal, Rafaela ^a   De Almeida, Sérgio F ^d   Carmo, Alexandre M ^a,e   Moreira, Alexandra ^a  

^a UNIVERSITY OF PORTO   (Portugal)

^b UNIVERSITY OF MINHO   (Portugal)

^c UNIVERSITY OF MINHO   (Portugal)

^d INSTITUTO DE MEDICINA MOLECULAR   (Portugal)

^e UNIVERSITY OF PORTO   (Portugal)

Author keywords

[No Author keywords available]

Indexed keywords

BINDING PROTEIN; CD6 ANTIGEN; PROTEIN SRSF1; RNA POLYMERASE II; UNCLASSIFIED DRUG;

ACETYLATION; ALTERNATIVE RNA SPLICING; ARTICLE; BINDING AFFINITY; CD6 GENE; CHROMATIN IMMUNOPRECIPITATION; CHROMATIN STRUCTURE; DOWN REGULATION; EXON SKIPPING; GENE; HISTONE MODIFICATION; HUMAN; HUMAN CELL; LIGAND BINDING; MOLECULAR MECHANICS; PRIORITY JOURNAL; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; T LYMPHOCYTE ACTIVATION; TRANSCRIPTION REGULATION;

ACETYLATION; ALTERNATIVE SPLICING; ANTIGEN-PRESENTING CELLS; ANTIGENS, CD; ANTIGENS, DIFFERENTIATION, T-LYMPHOCYTE; CELL ADHESION MOLECULES, NEURONAL; CHROMATIN; FEMALE; FETAL PROTEINS; HUMANS; INTRONS; LYMPHOCYTE ACTIVATION; MALE; NUCLEAR PROTEINS; RNA POLYMERASE II; RNA-BINDING PROTEINS; T-LYMPHOCYTES; TRANSCRIPTION, GENETIC;

EID: 84903626125     PISSN: 00221767     EISSN: 15506606     Source Type: Journal    
DOI: 10.4049/jimmunol.1400038     Document Type: Article

References (67)

1. Kamoun, M., M. E. Kadin, P. J. Martin, J. Nettleton, and J. A. Hansen. 1981. A novel human T cell antigen preferentially expressed on mature T cells and shared by both well and poorly differentiated B cell leukemias and lymphomas. J. Immunol. 127: 987-991.
2. Sarrias, M. R., J. Grønlund, O. Padilla, J. Madsen, U. Holmskov, and F. Lozano. 2004. The Scavenger Receptor Cysteine-Rich (SRCR) domain: an ancient and highly conserved protein module of the innate immune system. Crit. Rev. Immunol. 24: 1-37.
3. Hassan, N. J., S. J. Simmonds, N. G. Clarkson, S. Hanrahan, M. J. Puklavec, M. Bomb, A. N. Barclay, and M. H. Brown. 2006. CD6 regulates T-cell responses through activation-dependent recruitment of the positive regulator SLP-76. Mol. Cell. Biol. 26: 6727-6738. (Pubitemid 44277906)
4. Oliveira, M. I., C. M. Gonçalves, M. Pinto, S. Fabre, A. M. Santos, S. F. Lee, M. A. Castro, R. J. Nunes, R. R. Barbosa, J. R. Parnes, et al. 2012. CD6 attenuates early and late signaling events, setting thresholds for T-cell activation. Eur. J. Immunol. 42: 195-205.
5. Bott, C. M., J. B. Doshi, C. Morimoto, P. L. Romain, and D. A. Fox. 1993. Activation of human T cells through CD6: functional effects of a novel anti-CD6 monoclonal antibody and definition of four epitopes of the CD6 glycoprotein. Int. Immunol. 5: 783-792. (Pubitemid 23223682)
6. Castro, M. A., R. J. Nunes, M. I. Oliveira, P. A. Tavares, C. Simões, J. R. Parnes, A. Moreira, and A. M. Carmo. 2003. OX52 is the rat homologue of CD6: evidence for an effector function in the regulation of CD5 phosphorylation. J. Leukoc. Biol. 73: 183-190.
7. International MS Genetics Consortium. 2009. Meta-analysis of genome scans and replication identify CD6, IRF8 and TNFRSF1A as new multiple sclerosis susceptibility loci. Nat. Genet. 41: 776-782.
8. Swaminathan, B., F. Matesanz, M. L. Cavanillas, I. Alloza, D. Otaegui, J. Olascoaga, M. C. Cénit, V. de las Heras, M. G. Barcina, R. Arroyo, et al. 2010. Validation of the CD6 and TNFRSF1A loci as risk factors for multiple sclerosis in Spain. J. Neuroimmunol. 223: 100-103.
9. Rodriguez, P. C., R. Torres-Moya, G. Reyes, C. Molinero, D. Prada, A. M. Lopez, I. M. Hernandez, M. V. Hernandez, J. P. Martinez, X. Hernandez, et al. 2012. A clinical exploratory study with itolizumab, an anti-CD6 monoclonal antibody, in patients with rheumatoid arthritis. Res. Immunol. 2: 204-211.
10. Montero, E., L. Falcon, Y. Morera, J. Delgado, J. F. Amador, and R. Perez. 1999. CD6 molecule may be important in the pathological mechanisms of lymphocytes adhesion to human skin in psoriasis and ior t1 MAb a possible new approach to treat this disease. Autoimmunity 29: 155-156.
11. Alonso, R., C. Buors, C. Le Dantec, S. Hillion, J. O. Pers, A. Saraux, E. Montero, R. Marianowski, S. Loisel, V. Devauchelle, et al. 2010. Aberrant expression of CD6 on B-cell subsets from patients with Sjögren's syndrome. J. Autoimmun. 35: 336-341.
12. Pinto, M., and A. M. Carmo. 2013. CD6 as a therapeutic target in autoimmune diseases: successes and challenges. BioDrugs: clinical immunotherapeutics, biopharmaceuticals and gene therapy 27: 191-202.
13. Singer, N. G., D. A. Fox, T. M. Haqqi, L. Beretta, J. S. Endres, S. Prohaska, J. R. Parnes, J. Bromberg, and R. M. Sramkoski. 2002. CD6: expression during development, apoptosis and selection of human and mouse thymocytes. Int. Immunol. 14: 585-597. (Pubitemid 34649714)
14. Cayrol, R., K. Wosik, J. L. Berard, A. Dodelet-Devillers, I. Ifergan, H. Kebir, A. S. Haqqani, K. Kreymborg, S. Krug, R. Moumdjian, et al. 2008. Activated leukocyte cell adhesion molecule promotes leukocyte trafficking into the central nervous system. Nat. Immunol. 9: 137-145.
15. Bowen, M. A., J. Bajorath, A. W. Siadak, B. Modrell, A. R. Malacko, H. Marquardt, S. G. Nadler, and A. Aruffo. 1996. The amino-terminal immunoglobulin-like domain of activated leukocyte cell adhesion molecule binds specifically to the membrane-proximal scavenger receptor cysteine-rich domain of CD6 with a 1:1 stoichiometry. J. Biol. Chem. 271: 17390-17396. (Pubitemid 26244302)
16. Hassan, N. J., A. N. Barclay, and M. H. Brown. 2004. Frontline: Optimal T cell activation requires the engagement of CD6 and CD166. Eur. J. Immunol. 34:930-940. (Pubitemid 39255971)
17. Castro, M. A., M. I. Oliveira, R. J. Nunes, S. Fabre, R. Barbosa, A. Peixoto, M. H. Brown, J. R. Parnes, G. Bismuth, A. Moreira, et al. 2007. Extracellular isoforms of CD6 generated by alternative splicing regulate targeting of CD6 to the immunological synapse. J. Immunol. 178: 4351-4361. (Pubitemid 46492386)
18. Kofler, D. M., C. A. Severson, N. Mousissian, P. L. De Jager, and D. A. Hafler. 2011. The CD6 multiple sclerosis susceptibility allele is associated with alterations in CD4+ T cell proliferation. J. Immunol. 187: 3286-3291.
19. Martinez, N. M., and K. W. Lynch. 2013. Control of alternative splicing in immune responses: many regulators, many predictions, much still to learn. Immunol. Rev. 253: 216-236.
20. Seipelt, R. L., and M. L. Peterson. 1995. Alternative processing of IgA premRNA responds like IgM to alterations in the efficiency of the competing splice and cleavage-polyadenylation reactions. Mol. Immunol. 32: 277-285.
21. Matter, N., P. Herrlich, and H. König. 2002. Signal-dependent regulation of splicing via phosphorylation of Sam68. Nature 420: 691-695. (Pubitemid 36764503)
22. Heyd, F., and K. W. Lynch. 2010. Phosphorylation-dependent regulation of PSF by GSK3 controls CD45 alternative splicing. Mol. Cell 40: 126-137.
23. Goodwin, R. G., D. Friend, S. F. Ziegler, R. Jerzy, B. A. Falk, S. Gimpel, D. Cosman, S. K. Dower, C. J. March, A. E. Namen, et al. 1990. Cloning of the human and murine interleukin-7 receptors: demonstration of a soluble form and homology to a new receptor superfamily. Cell 60: 941-951.
24. Izquierdo, J. M., and J. Valcárcel. 2007. Fas-activated serine/threonine kinase (FAST K) synergizes with TIA-1/TIAR proteins to regulate Fas alternative splicing. J. Biol. Chem. 282: 1539-1543. (Pubitemid 47076675)
25. Ladd, A. N., and T. A. Cooper. 2002. Finding signals that regulate alternative splicing in the post-genomic era. Genome Biol. 3: reviews0008.
26. Graveley, B. R. 2000. Sorting out the complexity of SR protein functions. RNA 6:1197-1211.
27. Long, J. C., and J. F. Caceres. 2009. The SR protein family of splicing factors: master regulators of gene expression. Biochem. J. 417: 15-27.
28. Huelga, S. C., A. Q. Vu, J. D. Arnold, T. Y. Liang, P. P. Liu, B. Y. Yan, J. P. Donohue, L. Shiue, S. Hoon, S. Brenner, M. Ares, Jr., and G. W. Yeo. 2012. Integrative genome-wide analysis reveals cooperative regulation of alternative splicing by hnRNP proteins. Cell Rep. 1: 167-178.
29. Chasin, L. A. 2007. Searching for splicing motifs. Adv. Exp. Med. Biol. 623: 85-106.
30. Martinez-Contreras, R., P. Cloutier, L. Shkreta, J. F. Fisette, T. Revil, and B. Chabot. 2007. hnRNP proteins and splicing control. Adv. Exp. Med. Biol. 623: 123-147.
31. Shukla, S., E. Kavak, M. Gregory, M. Imashimizu, B. Shutinoski, M. Kashlev, P. Oberdoerffer, R. Sandberg, and S. Oberdoerffer. 2011. CTCF-promoted RNA polymerase II pausing links DNA methylation to splicing. Nature 479: 74-79.
32. Luco, R. F., Q. Pan, K. Tominaga, B. J. Blencowe, O. M. Pereira-Smith, and T. Misteli. 2010. Regulation of alternative splicing by histone modifications. Science 327: 996-1000.
33. Saint-André, V., E. Batsché, C. Rachez, and C. Muchardt. 2011. Histone H3 lysine 9 trimethylation and HP1γ favor inclusion of alternative exons. Nat. Struct. Mol. Biol. 18: 337-344.
34. Tilgner, H., C. Nikolaou, S. Althammer, M. Sammeth, M. Beato, J. Valcárcel, and R. Guigó. 2009. Nucleosome positioning as a determinant of exon recognition. Nat. Struct. Mol. Biol. 16: 996-1001.
35. Nogues, G., S. Kadener, P. Cramer, D. Bentley, and A. R. Kornblihtt. 2002. Transcriptional activators differ in their abilities to control alternative splicing. J. Biol. Chem. 277: 43110-43114. (Pubitemid 35285694)
36. Schwartz, S., E. Meshorer, and G. Ast. 2009. Chromatin organization marks exon-intron structure. Nat. Struct. Mol. Biol. 16: 990-995.
37. de Almeida, S. F., A. R. Grosso, F. Koch, R. Fenouil, S. Carvalho, J. Andrade, H. Levezinho, M. Gut, D. Eick, I. Gut, et al. 2011. Splicing enhances recruitment of methyltransferase HYPB/Setd2 and methylation of histone H3 Lys36. Nat. Struct. Mol. Biol. 18: 977-983.
38. Kadener, S., P. Cramer, G. Nogués, D. Cazalla, M. de la Mata, J. P. Fededa, S. E. Werbajh, A. Srebrow, and A. R. Kornblihtt. 2001. Antagonistic effects of T-Ag and VP16 reveal a role for RNA pol II elongation on alternative splicing. EMBO J. 20: 5759-5768.
39. Schor, I. E., N. Rascovan, F. Pelisch, M. Alló, and A. R. Kornblihtt. 2009. Neuronal cell depolarization induces intragenic chromatin modifications affecting NCAM alternative splicing. Proc. Natl. Acad. Sci. USA 106: 4325-4330.
40. Roberts, G. C., C. Gooding, H. Y. Mak, N. J. Proudfoot, and C. W. Smith. 1998. Co-transcriptional commitment to alternative splice site selection. Nucleic Acids Res. 26: 5568-5572. (Pubitemid 28554723)
41. Nogués, G., M. J. Muñoz, and A. R. Kornblihtt. 2003. Influence of polymerase II processivity on alternative splicing depends on splice site strength. J. Biol. Chem. 278: 52166-52171. (Pubitemid 38035803)
42. Ip, J. Y., D. Schmidt, Q. Pan, A. K. Ramani, A. G. Fraser, D. T. Odom, and B. J. Blencowe. 2011. Global impact of RNA polymerase II elongation inhibition on alternative splicing regulation. Genome Res. 21: 390-401.
43. Luco, R. F., M. Allo, I. E. Schor, A. R. Kornblihtt, and T. Misteli. 2011. Epigenetics in alternative pre-mRNA splicing. Cell 144: 16-26.
44. Bannister, A. J., R. Schneider, F. A. Myers, A. W. Thorne, C. Crane-Robinson, and T. Kouzarides. 2005. Spatial distribution of di- and tri-methyl lysine 36 of histone H3 at active genes. J. Biol. Chem. 280: 17732-17736. (Pubitemid 41389011)
45. Roh, T. Y., S. Cuddapah, and K. Zhao. 2005. Active chromatin domains are defined by acetylation islands revealed by genome-wide mapping. Genes Dev. 19: 542-552. (Pubitemid 40314987)
46. Hnilicová, J., S. Hozeifi, E. Dušková, J. Icha, T. Tománková, and D. Staněk. 2011. Histone deacetylase activity modulates alternative splicing. PLoS ONE 6: e16727.
47. Salmond, R. J., A. Filby, I. Qureshi, S. Caserta, and R. Zamoyska. 2009. T-cell receptor proximal signaling via the Src-family kinases, Lck and Fyn, influences T-cell activation, differentiation, and tolerance. Immunol. Rev. 228: 9-22.
48. Perez-Villar, J. J., G. S. Whitney, M. A. Bowen, D. H. Hewgill, A. A. Aruffo, and S. B. Kanner. 1999. CD5 negatively regulates the T-cell antigen receptor signal transduction pathway: involvement of SH2-containing phosphotyrosine phosphatase SHP-1. Mol. Cell. Biol. 19: 2903-2912. (Pubitemid 29144535)
49. Dennehy, K. M., R. Broszeit, W. F. Ferris, and A. D. Beyers. 1998. Thymocyte activation induces the association of the proto-oncoprotein c-cbl and ras GTPase-activating protein with CD5. Eur. J. Immunol. 28: 1617-1625. (Pubitemid 28221166)
50. Burgess, K. E., M. Yamamoto, K. V. Prasad, and C. E. Rudd. 1992. CD5 acts as a tyrosine kinase substrate within a receptor complex comprising T-cell receptor zeta chain/CD3 and protein-tyrosine kinases p56lck and p59fyn. Proc. Natl. Acad. Sci. USA 89: 9311-9315.
51. Bamberger, M., A. M. Santos, C. M. Gonçalves, M. I. Oliveira, J. R. James, A. Moreira, F. Lozano, S. J. Davis, and A. M. Carmo. 2011. A new pathway of CD5 glycoprotein-mediated T cell inhibition dependent on inhibitory phosphorylation of Fyn kinase. J. Biol. Chem. 286: 30324-30336.
52. Kornblihtt, A. R., I. E. Schor, M. Alló, G. Dujardin, E. Petrillo, and M. J. Muñoz. 2013. Alternative splicing: a pivotal step between eukaryotic transcription and translation. Nat. Rev. Mol. Cell Biol. 14: 153-165.
53. Pinto, P. A., T. Henriques, M. O. Freitas, T. Martins, R. G. Domingues, P. S. Wyrzykowska, P. A. Coelho, A. M. Carmo, C. E. Sunkel, N. J. Proudfoot, and A. Moreira. 2011. RNA polymerase II kinetics in polo polyadenylation signal selection. EMBO J. 30: 2431-2444.
54. de la Mata, M., C. Lafaille, and A. R. Kornblihtt. 2010. First come, first served revisited: factors affecting the same alternative splicing event have different effects on the relative rates of intron removal. RNA 16: 904-912.
55. Hartmann, B., and J. Valcárcel. 2009. Decrypting the genome's alternative messages. Curr. Opin. Cell Biol. 21: 377-386.
56. Wang, Z., and C. B. Burge. 2008. Splicing regulation: from a parts list of regulatory elements to an integrated splicing code. RNA 14: 802-813. (Pubitemid 351574901)
57. Witten, J. T., and J. Ule. 2011. Understanding splicing regulation through RNA splicing maps. Trends Genet. 27: 89-97.
58. Shaw, S. D., S. Chakrabarti, G. Ghosh, and A. R. Krainer. 2007. Deletion of the N-terminus of SF2/ASF permits RS-domain-independent pre-mRNA splicing. PLoS ONE 2: e854.
59. Sun, Q., A. Mayeda, R. K. Hampson, A. R. Krainer, and F. M. Rottman. 1993. General splicing factor SF2/ASF promotes alternative splicing by binding to an exonic splicing enhancer. Genes Dev. 7(12B): 2598-2608. (Pubitemid 24021016)
60. Xiao, S. H., and J. L. Manley. 1998. Phosphorylation-dephosphorylation differentially affects activities of splicing factor ASF/SF2. EMBO J. 17: 6359-6367. (Pubitemid 28497807)
61. Wang, J., S. H. Xiao, and J. L. Manley. 1998. Genetic analysis of the SR protein ASF/SF2: interchangeability of RS domains and negative control of splicing. Genes Dev. 12: 2222-2233. (Pubitemid 28348045)
62. Martins de Araújo, M., S. Bonnal, M. L. Hastings, A. R. Krainer, and J. Valcárcel. 2009. Differential 39 splice site recognition of SMN1 and SMN2 transcripts by U2AF and U2 snRNP. RNA 15: 515-523.
63. Anczuków, O., A. Z. Rosenberg, M. Akerman, S. Das, L. Zhan, R. Karni, S. K. Muthuswamy, and A. R. Krainer. 2012. The splicing factor SRSF1 regulates apoptosis and proliferation to promote mammary epithelial cell transformation. Nat. Struct. Mol. Biol. 19: 220-228.
64. Kanehiro, Y., K. Todo, M. Negishi, J. Fukuoka, W. Gan, T. Hikasa, Y. Kaga, M. Takemoto, M. Magari, X. Li, et al. 2012. Activation-induced cytidine deaminase (AID)-dependent somatic hypermutation requires a splice isoform of the serine/arginine-rich (SR) protein SRSF1. Proc. Natl. Acad. Sci. USA 109:1216-1221.
65. Lemaire, R., A. Winne, M. Sarkissian, and R. Lafyatis. 1999. SF2 and SRp55 regulation of CD45 exon 4 skipping during T cell activation. Eur. J. Immunol. 29: 823-837. (Pubitemid 29119061)
66. Schor, I. E., D. Lleres, G. J. Risso, A. Pawellek, J. Ule, A. I. Lamond, and A. R. Kornblihtt. 2012. Perturbation of chromatin structure globally affects localization and recruitment of splicing factors. PLoS ONE 7: e48084.
67. Edmond, V., E. Moysan, S. Khochbin, P. Matthias, C. Brambilla, E. Brambilla, S. Gazzeri, and B. Eymin. 2011. Acetylation and phosphorylation of SRSF2 control cell fate decision in response to cisplatin. EMBO J. 30: 510-523.